Open Access. Powered by Scholars. Published by Universities.®
Biochemistry, Biophysics, and Structural Biology Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Keyword
-
- HIV Protease (2)
- HIV-1 (2)
- *Drug Resistance, Viral (1)
- *Mutation, Missense (1)
- Anti-HIV Agents (1)
-
- Bifunctional enzyme (1)
- Carbamates (1)
- Catalytic activity (1)
- Crystallography, X-Ray (1)
- Cytosine Deaminase (1)
- Drug Resistance, Viral (1)
- Dynamic coupling (1)
- HCV NS3/4A (1)
- Humans (1)
- Interdomain communication (1)
- Kinetics (1)
- Models, Molecular (1)
- Mutant Proteins (1)
- Oligopeptides (1)
- Point Mutation (1)
- Protease-helicase interaction (1)
- Protein Binding (1)
- Protein Conformation (1)
- Pyridines (1)
- Sulfonamides (1)
- Thermodynamics (1)
- Vif Gene Products, Human Immunodeficiency Virus (1)
Articles 1 - 4 of 4
Full-Text Articles in Biochemistry, Biophysics, and Structural Biology
The Interdomain Interface In Bifunctional Enzyme Protein 3/4a (Ns3/4a) Regulates Protease And Helicase Activities, Cihan Aydin, Sourav Mukherjee, Alicia Hanson, David Frick, Celia Schiffer
The Interdomain Interface In Bifunctional Enzyme Protein 3/4a (Ns3/4a) Regulates Protease And Helicase Activities, Cihan Aydin, Sourav Mukherjee, Alicia Hanson, David Frick, Celia Schiffer
Celia A. Schiffer
Hepatitis C (HCV) protein 3/4A (NS3/4A) is a bifunctional enzyme comprising two separate domains with protease and helicase activities, which are essential for viral propagation. Both domains are stable and have enzymatic activity separately, and the relevance and implications of having protease and helicase together as a single protein remains to be explored. Altered in vitro activities of isolated domains compared with the full-length NS3/4A protein suggest the existence of interdomain communication. The molecular mechanism and extent of this communication was investigated by probing the domain-domain interface observed in HCV NS3/4A crystal structures. We found in molecular dynamics simulations that …
Cooperative Effects Of Drug-Resistance Mutations In The Flap Region Of Hiv-1 Protease, Jennifer Foulkes-Murzycki, Christina Rosi, Nese Yilmaz, Robert Shafer, Celia Schiffer
Cooperative Effects Of Drug-Resistance Mutations In The Flap Region Of Hiv-1 Protease, Jennifer Foulkes-Murzycki, Christina Rosi, Nese Yilmaz, Robert Shafer, Celia Schiffer
Celia A. Schiffer
Understanding the interdependence of multiple mutations in conferring drug resistance is crucial to the development of novel and robust inhibitors. As HIV-1 protease continues to adapt and evade inhibitors while still maintaining the ability to specifically recognize and efficiently cleave its substrates, the problem of drug resistance has become more complicated. Under the selective pressure of therapy, correlated mutations accumulate throughout the enzyme to compromise inhibitor binding, but characterizing their energetic interdependency is not straightforward. A particular drug resistant variant (L10I/G48V/I54V/V82A) displays extreme entropy-enthalpy compensation relative to wild-type enzyme but a similar variant (L10I/G48V/I54A/V82A) does not. Individual mutations of sites …
Structural And Thermodynamic Basis Of Amprenavir/Darunavir And Atazanavir Resistance In Hiv-1 Protease With Mutations At Residue 50, Seema Mittal, Rajintha Bandaranayake, Nancy King, Moses Prabu-Jeyabalan, Madhavi Nalam, Ellen Nalivaika, Nese Yilmaz, Celia Schiffer
Structural And Thermodynamic Basis Of Amprenavir/Darunavir And Atazanavir Resistance In Hiv-1 Protease With Mutations At Residue 50, Seema Mittal, Rajintha Bandaranayake, Nancy King, Moses Prabu-Jeyabalan, Madhavi Nalam, Ellen Nalivaika, Nese Yilmaz, Celia Schiffer
Celia A. Schiffer
Drug resistance occurs through a series of subtle changes that maintain substrate recognition but no longer permit inhibitor binding. In HIV-1 protease, mutations at I50 are associated with such subtle changes that confer differential resistance to specific inhibitors. Residue I50 is located at the protease flap tips, closing the active site upon ligand binding. Under selective drug pressure, I50V/L substitutions emerge in patients, compromising drug susceptibility and leading to treatment failure. The I50V substitution is often associated with amprenavir (APV) and darunavir (DRV) resistance, while the I50L substitution is observed in patients failing atazanavir (ATV) therapy. To explain how APV, …
Crystal Structure Of The Dna Cytosine Deaminase Apobec3f: The Catalytically Active And Hiv-1 Vif-Binding Domain, Markus-Frederik Bohn, Shivender Shandilya, John Albin, Takahide Kouno, Brett Anderson, Rebecca Mcdougle, Michael Carpenter, Anurag Rathore, Leah Evans, Ahkillah Davis, Jingying Zhang, Yongjian Lu, Mohan Somasundaran, Hiroshi Matsuo, Reuben Harris, Celia Schiffer
Crystal Structure Of The Dna Cytosine Deaminase Apobec3f: The Catalytically Active And Hiv-1 Vif-Binding Domain, Markus-Frederik Bohn, Shivender Shandilya, John Albin, Takahide Kouno, Brett Anderson, Rebecca Mcdougle, Michael Carpenter, Anurag Rathore, Leah Evans, Ahkillah Davis, Jingying Zhang, Yongjian Lu, Mohan Somasundaran, Hiroshi Matsuo, Reuben Harris, Celia Schiffer
Celia A. Schiffer
Human APOBEC3F is an antiretroviral single-strand DNA cytosine deaminase, susceptible to degradation by the HIV-1 protein Vif. In this study the crystal structure of the HIV Vif binding, catalytically active, C-terminal domain of APOBEC3F (A3F-CTD) was determined. The A3F-CTD shares structural motifs with portions of APOBEC3G-CTD, APOBEC3C, and APOBEC2. Residues identified to be critical for Vif-dependent degradation of APOBEC3F all fit within a predominantly negatively charged contiguous region on the surface of A3F-CTD. Specific sequence motifs, previously shown to play a role in Vif susceptibility and virion encapsidation, are conserved across APOBEC3s and between APOBEC3s and HIV-1 Vif. In this …